17:54 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Synthetic fusion protein system for EGFR- and HER2-positive cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; brain cancer; non-small cell lung cancer (NSCLC); pancreatic cancer In vitro studies suggest a synthetic fusion protein-based system could help treat EGFR- or HER2-positive cancers. The system consists of...
21:31 , May 23, 2019 |  BC Innovations  |  Translation in Brief

Synthetic biology redirects oncogenic signaling against cancer

Stanford scientists have used synthetic biology to turn cancer cell signaling against tumors by harnessing EGF receptor signaling instead of inhibiting it, and might spin out a company to develop the technology. The Stanford University...
22:33 , Mar 27, 2019 |  BC Innovations  |  Translation in Brief

A mitochondrial shield from cell death

An IBM-Mount Sinai team has challenged the prevailing idea that high mitochondrial counts in tumor cells enhance cancer’s sensitivity to apoptosis-inducing therapies by showing that low numbers of the organelle actually do the trick. The...
01:49 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

CTI withdraws MAA for myleofibrosis therapy

CTI BioPharma Corp. (NASDAQ:CTIC) withdrew its MAA for pacritinib to treat myelofibrosis following interactions with EMA's CHMP suggesting the committee was likely to issue a negative opinion. CTI said CHMP indicated the risk-benefit profile of...
21:12 , Feb 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ajovy, Vizimpro, Humira biosimilars

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Ajovy fremanezumab, Vizimpro dacomitinib and two Humira biosimilars. CHMP also backed an expanded label for Forxiga dapagliflozin to include Type I diabetes....
22:41 , Nov 8, 2018 |  BC Innovations  |  Product R&D

JLABS seeks lung cancer solutions in Shanghai

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities. Chan sees opportunity in China...
20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
18:17 , Sep 28, 2018 |  BC Week In Review  |  Company News

Opiant gets BARDA grant for intranasal opioid antagonist

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant...
23:13 , Sep 20, 2018 |  BC Extra  |  Company News

Opiant gets BARDA grant for intranasal opioid antagonist

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant...
00:46 , Aug 4, 2018 |  BioCentury  |  Finance

Functions of formulation

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can...